Neoadjuvant and Adjuvant Toripalimab for Locoregionally Advanced Nasopharyngeal Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial
Lancet Oncol 2024 Nov 07;[EPub Ahead of Print], SL Liu, XY Li, JH Yang, DX Wen, SS Guo, LT Liu, YF Li, MJ Luo, SY Xie, YJ Liang, XS Sun, ZC Yang, XF Lv, DH Luo, JB Li, Q Liu, P Wang, L Guo, HY Mo, R Sun, Q Yang, KQ Lan, GD Jia, R Li, C Zhao, RH Xu, QY Chen, LQ Tang, HQ MaiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.